News | July 06, 2024
Biogen completes acquisition of HI-Bio
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Subscribe To Our Newsletter & Stay Updated
